skip to primary navigationskip to content
 

Imaging Neurodegeneration

Imaging Neurodegeneration

Target: a-synuclein, tau protein, amyloid-b, OPC

PET radiotracer candidates: EMF26, LM229, OT049

Alzheimer’s, Parkinson’s, Huntington’s Disease, dementia with Lewy Bodies, and multiple sclerosis are characterised by the progressive loss of neurons and are classed as neurodegenerative diseases. The underlying pathology is a result of the formation of insoluble fibrillar inclusions which are under normal conditions unfolded and soluble. These fibrillar inclusions are known as plaques (amyloid-b), neurofibrillary tangles (tau) and Lewy Bodies (a-synuclein). As a non-invasive and functional imaging technique PET can allow for visualization of aggregates, as well as their quantification thus offering a powerful tool in diagnosis and disease monitoring.

In our group, we are developing selective PET imaging probes for each of the known aggregates. We have recently identified LM229 as a promising new PET candidate for imaging tau which compared favourably to known PBB3 analogue.

In addition, we have recently commenced research into multiple sclerosis where we target progenitor cells

Immunohistochemistry of LM229